Sannah Zoffmann

Biog:
Following a M.Sc. in Biochemistry Dr. Zoffmann did her Ph.D. at Copenhagen and Strasbourg Universities on the structure and pharmacology of chemokine and neurokinin receptors. She joined F. Hoffmann-La Roche AG in 2002 in the area of Cardiovascular and Metabolic Diseases. In 2005 Dr. Zoffmann built up the first high-content screening capability at Roche where she currently heads the HCS platform in the Target Identification Group in Discovery Technologies. Her current includes projects in the areas of Neuroscience, Infectious diseases, and Oncology.